Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.

Teresa  Macarulla

Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; Arcus Biosciences; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks

Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER

Michael  Cecchini

Stock and Other Ownership Interests  - Parthenon Therapeutics

Honoraria - Agenus; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; Incendia Therapeutics; Loxo/Lilly; Macrogenics; Regeneron; Seagen; Taiho Oncology

Rocio  Garcia-Carbonero

Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; Astellas Pharma; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim; Esteve; Gilead Sciences (I); Hutchmed; Ipsen; Lilly (I); Merck; Midatech Pharma; Mirati Therapeutics (I); MSD; Pfizer (I); PharmaMar; Roche (I); Sanofi (I); Servier; Takeda

Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst)

Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Esteve; Ipsen; Merck; MSD

Talia  Golan

Honoraria - Abbvie; AstraZeneca/MedImmune; MSD

Consulting or Advisory Role - Abbvie; AstraZeneca

Speakers' Bureau - AstraZeneca; MSD Oncology

Research Funding - AstraZeneca (Inst); MSD (Inst)

Ruth  Perets

Employment - Rambam Health Care Campus

Honoraria - GlaxoSmithKline

Consulting or Advisory Role - 1E Therapeutics; GalMed Pharmacueticals; Simplivia

Research Funding - 1E Therapeutics

Erkut Hasan  Borazanci

Consulting or Advisory Role - Boehler Life Science Advice; BPGbio; ClearNote Health; Conjupro Biotherapeutics; Elevation Oncology; NanOlogy; Qurient; TD2; Vivacitus

Research Funding - BioNTech (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst)

Manuel  Pedregal

No Relationships to Disclose

Mariano  Ponz-Sarvise

Consulting or Advisory Role - AstraZeneca Spain

Travel, Accommodations, Expenses - AstraZeneca (Inst); Incyte; Oncosil

Mohammed Najeeb  Al Hallak

Speakers' Bureau - AstraZeneca; Guardant Health; Ipsen; Seagen; Takeda

Shubham  Pant

Consulting or Advisory Role - Alligator Bioscience; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Nihon Medi-Physics; Novartis; US WorldMeds; Zymeworks

Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)

Valentina  Boni

Employment - Next Oncology; Quironsalud

Leadership - Next Oncology (Inst)

Stock and Other Ownership Interests  - 1TRIALSP

Honoraria - Amunix; EMD Serono/Merck; Guidepoint Global; IDEAYA Biosciences; Janssen; Loxo; MSD Oncology; Puma Biotechnology

Consulting or Advisory Role - EMD Serono/Merck; Guidepoint Global; Janssen Research & Development; Lilly; Nanobiotix; Novartis; OncoArt

Speakers' Bureau - Lilly; MSD; Solti; Tactics

Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)

Travel, Accommodations, Expenses - Bayer; START

Omar  Saavedra

Travel, Accommodations, Expenses - Affimed Therapeutics

Maria J.  de Miguel

Honoraria - Janssen; MSD Oncology; Roche

(OPTIONAL) Uncompensated Relationships - Abbvie; Array BioPharma; Eisai; Genmab; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Sanofi

Alexis Diane  Leal

Employment - Elsevier

Leadership - Elsevier

Research Funding - Abbvie (Inst); Arrys Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conjupro Biotherapeutics (Inst); Corcept Therapeutics (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); Takeda (Inst)

Andrés J.  Muñoz Martín

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Pfizer; Celgene; Daiichi Sankyo; GlaxoSmithKline; Incyte; LEO Pharma; Lilly; MSD Oncology; Roche; Sanofi; SERVIER

Speakers' Bureau - Bayer; Menarini; Rovi; SERVIER; STADA

Research Funding - Celgene; LEO Pharma; Rovi; Sanofi

Patents, Royalties, Other Intellectual Property - Risk assessment model in venous thromboembolism in cancer patients

Travel, Accommodations, Expenses - Amgen; Celgene; Merck Serono; Pfizer; Roche; SERVIER

Tamara  Sauri

No Relationships to Disclose

Michael  Schickler

Employment - Purple Biotech

Stock and Other Ownership Interests  - Purple Biotech